David Hava

David Hava

Company: Synlogic Therapeutics

Job title: Chief Scientific Officer

Bio:

Dr. David Hava has served as Synlogic’s Chief Scientific Officer since September, 2020. Dave is a microbiologist and immunologist with over 14 years of experience in the pharmaceutical industry leading platform and drug development programs. Prior to joining Synlogic, he was the Chief Scientific Officer at Metera Pharmaceuticals, an early stage company developing novel therapies for serious respiratory diseases. Previously, he was the Chief Scientific Officer at Pulmatrix Inc, where he led Research, Development and Clinical teams focused on the development of respiratory therapies in a novel dry powder delivery technology, called iSPERSE.  In his role as CSO, he led the company’s therapeutic strategy to identify and prioritize drug targets, and oversaw the advancement of multiple clinical programs into Phase 2 clinical development. Dave joined Pulmatrix in 2006 as one of the first Senior Scientists and was heavily involved in the early stage research and development programs that identified and characterized several of the key aspects of the Pulmatrix technology. He earned his PhD. in Molecular Biology and Microbiology at Tufts University and completed his post-doctoral training studying immunology and host-pathogen interactions at Harvard Medical School. As a post-doctoral fellow Dave was awarded a Damon Runyan Cancer Research Fellowship.  He has co-authored numerous manuscripts and abstracts focused on infectious disease, immunology, chronic lung diseases and platform development.

Seminars:

Speaker Q&A 1:05 pm

Read more

day: Day Two

Opening Remarks from Chairperson 3:45 pm

Read more

day: Day Two

Opening Remarks from Chairperson 1:45 pm

Read more

day: Day Two

Reprogramming the Tumor Microenvironment via engineered bacterial delivery of immune effectors: SYNB1891, a STING agonist 12:10 pm

SYNB1891: Phase 1, Dose Escalation Study as a mono and combo treatment (atezolizumab) in multi-solid tumors and lymphoma Synthetic Biology Effector Delivery Dual Action: Ability to stimulate the innate and adaptive immune systemRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.